Aura Biosciences is a clinical-stage biopharmaceutical company that is developing a new class of therapies to target and selectively destroy cancer cells. The company's lead product candidate, AU-011, is a first-in-class targeted therapy for the treatment of ocular melanoma, a rare and aggressive form of eye cancer. Aura's technology platform is based on virus-like particles that are engineered to deliver potent cancer-killing agents directly to tumor cells while sparing healthy tissue. The company is committed to advancing its pipeline of innovative cancer therapies to improve the lives of patients.